SynthesisBMC public health2025
Cancer risks of hematopoietic/lymphatic and urinary system in pharmaceutical plant workers: a systematic review and meta-analysis.
Synthesis in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn this study, we will investigate the risk of hematopoietic/lymphatic system and urinary system cancers in pharmaceutical plant workers.
methodsSix pre-defined inclusion criteria were applied. The quality of all included studies was assessed based on the National Toxicology Program Office of Health Assessment and Translation Risk of Bias tool. Conventional meta-analysis was conducted for hematopoietic/lymphatic system and urinary system cancers. Between-study heterogeneity and publication bias were investigated.
resultsIn this systematic review and meta-analysis, four cohort studies of a single pharmaceutical plant, one case-control study, and one cohort study with a nested case-control study were included. For publication bias, the p-value for Egger's regression test was 0.51 and 0.38 for hematopoietic/lymphatic and urinary system cancer, respectively. Pharmaceutical plant workers showed a 3.19 (95% confidence interval, CI 1.53-6.64) times higher risk of hematopoietic/lymphatic system cancers than the general population. They also showed a 4.86 (95% CI 1.71-13.80) times higher risk of urinary system cancers compared to the general population. Higgins' I-squared value for between-study heterogeneity was 61.77% (95% CI 0.00-99.06%) and 58.00% (95% CI 0.00-98.67%), respectively.
conclusionFrom this systematic review and meta-analysis, the authors concluded that potential hazardous occupational exposures of workers in pharmaceutical plants could pose an increased risk of hematopoietic/lymphatic system and urinary system cancer. Future studies should be conducted with a more thorough dose-response relationship distinction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.